Announcement on Notice of Approval for Clinical Trial of HK.3-JN.1 Novel Coronavirus mRNA Vaccine

Chongqing Zhifei Biological Products Co., Ltd.·February 26, 2026·2 pages

✨ AI Summary

Chongqing Zhifei Biological Products Co., Ltd. announced that its subsidiary's self-developed HK.3-JN.1 mRNA vaccine for novel coronavirus has received approval for clinical trials from China's NMPA. This marks a step forward in the company's R&D efforts and aims to address viral mutations. The approval is not expected to significantly impact short-term performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300122 Securities Abbreviation: Zhifei Biological Announcement No.: 2026-12

Chongqing Zhifei Biological Products Co., Ltd. Announcement on Notice of Approval for Clinical Trial of HK.3-JN.1 Novel Coronavirus mRNA Vaccine

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.

Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as the "Company") recently received a report from its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zhifei Longcom") stating that the HK.3-JN.1 novel coronavirus mRNA vaccine, independently developed by Zhifei Longcom, has received a Notice of Approval for Drug Clinical Trial from the National Medical Products Administration (Notice No.: 2026LP00481), agreeing to conduct a clinical trial for the prevention of diseases caused by novel coronavirus infection.

I. Project Introduction

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.